IMAP is pleased to announce that Degroof Petercam Investment Banking (“DPIB”) – IMAP France acted as financial advisor to EB Development in the context of the public tender offer (the “Offer”) on Eurobio Scientific (the “Company”) shares. Banque Degroof Petercam acted as presenting bank.

644,911 ordinary shares were tendered to the reopened Offer, which closed on 17 December 2024. These are in addition to the 4,582,971 ordinary shares tendered to the initial Offer, giving a total of 5,227,882 ordinary shares tendered to the Offer, enabling EB Development, acting in conjunction with funds managed by NextStage AM and IK Partners, and Mr. Denis Fortier, Chairman and CEO, and other members of the Board of Directors and senior management of the Company, to hold, after assimilation of the treasury shares held by Eurobio Scientific, 9,113,592 shares representing 88.92% of the share capital and voting rights of the Company.

NextStage AM and IK Partners, as core shareholders, will continue to support the group's team of entrepreneurs in this new stage of the Company’s growth.

Eurobio Scientific is a major player in the field of speciality in vitro diagnostics. It is involved in the research and marketing of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and offers dedicated reagents to research laboratories, including pharmaceutical and biotechnology companies.